Bolt Biotherapeutics, Inc. (BOLT)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
3.82 USD
-0.18
(-4.623%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.78 -0.04 (-0.040%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:47 a.m. EDT
The investment case for this biotechnology firm has collapsed entirely. Fundamentally, the company is hemorrhaging cash with negative operating margins exceeding 1,500%, burning nearly $32 million in operating cash flow, and reporting a massive 99.7% revenue contraction year-over-year. The balance sheet is precarious, with debt significantly outweighing equity and free cash flow deeply negative. This is not a value opportunity; it is a distressed asset facing existential threats. The operational reality is stark: the company recently announced layoffs and the abandonment of its lead ADC candidate, signaling a severe strategic retreat. While a new analyst initiated a 'buy' rating with a lofty $75 price target, this appears to be a speculative gamble on a potential turnaround rather than a reflection of current business health, especially given the median target of just $7. The stock has endured a catastrophic four-year decline, losing over 98% of its value, with every single year showing negative returns. There is no evidence of stabilization or recovery in the multi-year trajectory. Technically, the stock is trapped in a downtrend, trading well below both its 50-day and 200-day moving averages, reflecting persistent selling pressure. With no dividend to provide income and a business model currently failing to generate revenue or profit, there is no rational basis for a long-term hold or a short-term trade without significant downside risk. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.064451 |
| MSTL | 0.089834 |
| AutoETS | 0.092381 |
| AutoARIMA | 0.093030 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 7.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.014 |
| Excess Kurtosis | 0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 171.076 |
| Revenue per Share | 2.68 |
| Market Cap | 7,349,006 |
| Forward P/E | -0.19 |
| Beta | 1.08 |
| Website | https://www.boltbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.19678712 |
| Address1 | 900 Chesapeake Drive |
| All Time High | 861.4 |
| All Time Low | 3.13 |
| Ask | 5.1 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 18,100 |
| Average Daily Volume3 Month | 24,451 |
| Average Volume | 24,451 |
| Average Volume10Days | 18,100 |
| Beta | 1.083 |
| Bid | 2.9 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 6.562 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.815 |
| Current Ratio | 2.614 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.27 |
| Day Low | 3.74 |
| Debt To Equity | 171.076 |
| Display Name | Bolt Biotherapeutics |
| Earnings Call Timestamp End | 1,715,718,600 |
| Earnings Call Timestamp Start | 1,715,718,600 |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -27,556,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.413 |
| Enterprise To Revenue | 2.42 |
| Enterprise Value | 11,375,006 |
| Eps Current Year | -26.285 |
| Eps Forward | -20.19 |
| Eps Trailing Twelve Months | -16.51 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.90432 |
| Fifty Day Average Change | -0.089319944 |
| Fifty Day Average Change Percent | -0.022877209 |
| Fifty Two Week Change Percent | -19.67871 |
| Fifty Two Week High | 7.2 |
| Fifty Two Week High Change | -3.3849998 |
| Fifty Two Week High Change Percent | -0.47013888 |
| Fifty Two Week Low | 3.13 |
| Fifty Two Week Low Change | 0.68499994 |
| Fifty Two Week Low Change Percent | 0.21884981 |
| Fifty Two Week Range | 3.13 - 7.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 1,677,558 |
| Forward Eps | -20.19 |
| Forward P E | -0.18895492 |
| Free Cashflow | -18,791,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Fullday Change | -0.1849 |
| Fullday Change Percent | -4.62262 |
| Fullday Price | 3.775 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -16,801,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.034649998 |
| Held Percent Institutions | 0.27919 |
| Implied Shares Outstanding | 1,926,345 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,749,427,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. |
| Long Name | Bolt Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 7,349,006 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_297390520 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -28,739,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,705,187 |
| Number Of Analyst Opinions | 3 |
| Open | 3.97 |
| Operating Cashflow | -31,451,000 |
| Operating Margins | -1,513.2 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 665 9295 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -1.0484917 |
| Post Market Price | 3.775 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 3.9999 |
| Price Eps Current Year | -0.14513981 |
| Price Hint | 4 |
| Price To Book | 0.5813777 |
| Price To Sales Trailing12 Months | 1.5636183 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.239 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.18490005 |
| Regular Market Change Percent | -4.622617 |
| Regular Market Day High | 4.27 |
| Regular Market Day Low | 3.74 |
| Regular Market Day Range | 3.74 - 4.27 |
| Regular Market Open | 3.97 |
| Regular Market Previous Close | 3.9999 |
| Regular Market Price | 3.815 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 24,956 |
| Return On Assets | -0.30726 |
| Return On Equity | -1.11647 |
| Revenue Growth | -0.997 |
| Revenue Per Share | 2.68 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 1,926,345 |
| Shares Percent Shares Out | 0.0004 |
| Shares Short | 770 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,761 |
| Short Name | Bolt Biotherapeutics, Inc. |
| Short Percent Of Float | 0.0004 |
| Short Ratio | 0.03 |
| Source Interval | 15 |
| State | CA |
| Symbol | BOLT |
| Target High Price | 75.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 29.0 |
| Target Median Price | 7.0 |
| Total Cash | 17,598,000 |
| Total Cash Per Share | 9.135 |
| Total Debt | 21,624,000 |
| Total Revenue | 4,700,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -16.51 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.76277 |
| Two Hundred Day Average Change | -0.9477701 |
| Two Hundred Day Average Change Percent | -0.19899556 |
| Type Disp | Equity |
| Volume | 24,956 |
| Website | https://www.boltbio.com |
| Zip | 94,063 |